- LLY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $606.9 million.
- LLY traded 21,561 shares today in the pre-market hours as of 9:27 AM.
- LLY is up 2.4% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in LLY with the Ticky from Trade-Ideas. See the FREE profile for LLY NOW at Trade-Ideas More details on LLY: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The stock currently has a dividend yield of 2.4%. LLY has a PE ratio of 4. Currently there are 7 analysts that rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for Eli Lilly and has been 4.9 million shares per day over the past 30 days. Eli Lilly and has a market cap of $92.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.43 and a short float of 2.4% with 3.51 days to cover. Shares are up 19.8% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Highlights from the ratings report include:
- The gross profit margin for LILLY (ELI) & CO is currently very high, coming in at 83.39%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, LLY's net profit margin of 11.40% significantly trails the industry average.
- Compared to its closing price of one year ago, LLY's share price has jumped by 38.42%, exceeding the performance of the broader market during that same time frame. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
- The current debt-to-equity ratio, 0.55, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.95 is somewhat weak and could be cause for future problems.
- Regardless of the drop in revenue, the company managed to outperform against the industry average of 2.1%. Since the same quarter one year prior, revenues slightly dropped by 0.8%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- LILLY (ELI) & CO's earnings per share declined by 26.5% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, LILLY (ELI) & CO reported lower earnings of $2.23 versus $4.31 in the prior year. This year, the market expects an improvement in earnings ($3.16 versus $2.23).
- You can view the full Eli Lilly and Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.